Revenue
2018
2019
2020
2021
2022
2023
2024
2025
BioNexus Gene Lab Corp (BGLC)
Price$1.45Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M | $126,955 | $212,328 |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M | $1.7M | $55,888 | $28,765 |
| Gross margin | 14.62% | 13.56% | 13.61% | 11.52% | 16.96% | 15.10% | 44.02% | 13.55% |
| Research & development | $50,670 | $47,511 | $54,982 | — | — | — | — | — |
| Operating expenses | $4.5M | $4.9M | $4.4M | $1.6M | $1.2M | $446,001 | $331,593 | — |
| Operating income | −$3.0M | −$1.6M | −$2.6M | −$291,177 | $1.1M | $1.3M | −$275,705 | $59,901 |
| Operating margin | −39.93% | −16.55% | −26.54% | −2.66% | 7.90% | 11.18% | −217.17% | 28.21% |
| EBITDA | −$2.9M | −$1.4M | −$2.5M | −$185,758 | $1.2M | $1.4M | −$233,991 | $100,512 |
| EBITDA margin | −38.43% | −14.94% | −25.43% | −1.70% | 8.71% | 12.08% | −184.31% | 47.34% |
| Net income | −$3.0M | −$1.6M | −$2.6M | −$355,966 | $751,571 | $1.1M | −$246,469 | $26,454 |
| Net profit margin | −40.20% | −16.81% | −26.91% | −3.26% | 5.62% | 9.61% | −194.14% | 12.46% |
| Basic EPSper basic share | -$1.61 | -$0.90 | -$1.83 | -$0.46 | $0.48 | $1.44 | $0.00 | $0.00 |
| Diluted EPSper diluted share | -$1.61 | -$0.90 | -$1.66 | -$0.46 | $0.48 | $1.44 | $0.00 | $0.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
HRT FINANCIAL LP | 14.28K |
UBS Group AG | 101 |
Caitong International Asset Management Co., Ltd | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data